Project Area 3

Using a combination of prospective clinical cohorts, traditional and next-generation immunophenotyping approaches, and patient-specific human iPSC disease models, we aim to identify biomarkers and therapeutic targets for cardiovascular inflammatory and cardio-oncology diseases. Our lab integrates single-cell and spatial transcriptomics, TCR sequencing, CyTOF, plasma cell-free RNA profiling, and high-dimensional immune profiling with mechanistic human iPSC-based cardiac models to better understand why certain patients develop severe immune-mediated cardiovascular toxicity while others remain protected. By combining deep multi-omics profiling with translational experimental systems, we seek to develop precision medicine approaches that improve disease prediction, early diagnosis, risk stratification, and individualized treatment strategies for patients with inflammatory heart disease and cancer therapy-related cardiotoxicity.